

Cover Story
Free
An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.
In Brief
Funding Opportunities
Trending Stories
- Betty Ford and the press conference that changed oncology
- Robert Winn, Rebecca Miksad, Dana Rollison: We must use real-world data and lessons from COVID to improve care, equity in communities we serve
- Bipartisan misgivings: House appropriators chafe at Biden’s proposal to fund ARPA-H at the expense of NIH
- Cancer is complex and dynamic—ergo, dose optimization calls for mathematical modeling
- Equity and action: Ida Spruill and Walter Lawrence
- Chernobyl: a 35 year follow up on long-term health effects